Monopar Therapeutics Inc. MNPR stock is skyrocketing on Thursday. The company agreed with AstraZeneca Plc's AZN Alexion for an exclusive worldwide license to ALXN-1840 (bis-choline tetrathiomolybdate) for Wilson's disease. Monopar will be responsible for all future global development and commercialization activities. Also Read: Why Monopar Therapeutics (MNPR) Stock Is Skyrocketing Today Under the terms of the license agreement, Monopar will pay Alexion an upfront cash payment and equity in Monopar. Future p ...

BOSTON, Mass. and SHANGHAI, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, announced that it will receive a $60 million payment from AstraZeneca, which is being triggered by successfully achieving milestones related to the development of ECC5004/AZD5004 including the first patient dosed in the Phase 2b program. VISTA (NCT06579092) and SOLSTICE (NCT06579 ...

AstraZeneca (AZN) and Ionis Pharmaceuticals (IONS) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended approval for their drug Wainzua (eplontersen) for treating hereditary transthyretin-mediated amyloidosis, commonly called hATTR-PN or ATTRv-PN.If the European Commission approves Wainzua, it will become the only medicine approved for treating ATTRv-PN that can be self-administered monthly via an auto-injector in the European Union.Wainzua was approved by the name of Wai ...

Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Astrazeneca (AZN) and Novo Nordisk (NVO) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets companies with p ...

Astrazeneca (AZN) has been beaten down lately with too much selling pressure. While the stock has lost 5.3% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that ...

AstraZeneca (AZN) announced that it has signed an exclusive license agreement with China-based CSPC Pharmaceutical Group Ltd for developing an early-stage, small molecule Lipoprotein (a) (Lp(a)) disruptor for helping patients with dyslipidaemia. The latest agreement is likely to strengthen AstraZeneca's cardiovascular pipeline, which is being studied for treating various cardiovascular diseases. Image Source: Zacks Investment Research Year to date, shares of AstraZeneca have rallied 14.1% compared with the ...

For Immediate ReleaseChicago, IL – October 8, 2024 – Today, Zacks Equity Research Eli Lilly (LLY) , AstraZeneca (AZN) , Pfizer (PFE) , Sanofi (SNY) and Bayer (BAYRY) .Industry: Big PharmaLink: https://www.zacks.com/commentary/2346520/5-large-drug-stocks-to-watch-from-a-thriving-industryThe drug and biotech industry has done well this year, driven by increased mergers and acquisitions (M&A), the launch of promising new medicines and pipeline successes. Obesity drugs of Novo Nordisk and Eli Lilly have witness ...

AstraZeneca has entered into an exclusive licensing agreement with CSPC Pharmaceutical Group to advance the development of a novel preclinical small molecule lipoprotein(a) (Lp(a)) inhibitor.Under this agreement, AstraZeneca will gain access to CSPC's preclinical candidate YS2302018, an oral Lp(a) inhibitor. This drug is aimed at developing a new lipid-lowering therapy and can be used as a standalone or combination treatment for various cardiovascular diseases, including in combination with the oral small m ...

Core Insights - The BATURA Phase IIIb trial for AstraZeneca's Airsupra (albuterol/budesonide) has shown positive results, demonstrating a statistically significant reduction in the risk of severe asthma exacerbations compared to albuterol alone [1][2][3] - Airsupra is the first anti-inflammatory rescue medication approved in the US for asthma treatment, targeting patients aged 18 and older [3][8] - The trial included patients with intermittent or mild persistent asthma, highlighting the need for effective treatments in this population [2][7] Company Collaboration - Avillion Life Sciences conducted the BATURA trial under an exclusive co-development agreement with AstraZeneca, which has been in place since March 2018 [5][9] - The collaboration has been extended to further assess Airsupra's role in reducing asthma exacerbations, showcasing the value of their clinical co-development model [5][9] Clinical Development - The BATURA trial involved a randomized, double-blind design, comparing inhaled albuterol/budesonide as a rescue medication against albuterol alone for up to 12 months [7] - The primary endpoint was the time to first severe asthma exacerbation, with secondary endpoints including severe exacerbation rate and total systemic corticosteroid use [7] Market Context - Asthma affects approximately 262 million people globally, with over 25 million in the US, indicating a significant market for effective treatments [2][6] - Patients with mild asthma represent at least 50% of the US asthma population, emphasizing the importance of addressing their treatment needs [2][6] Future Directions - Airsupra is also being studied in adolescents and patients in China, indicating ongoing research and potential market expansion [3][8] - The positive results from the BATURA trial will be presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting, further promoting the drug's profile [2]

AstraZeneca (AZN) announced that the FDA has accepted the supplemental new drug application (sNDA), seeking approval for the expanded use of Calquence (acalabrutinib) in mantle cell lymphoma (MCL).The company is seeking approval for Calquence for the treatment of adult patients with previously untreated MCL, a rare and aggressive form of non-Hodgkin lymphoma. In the MCL indication, Calquence is currently approved for treating adult patients with MCL who have received at least one prior therapy in the United ...